Patents by Inventor Kelly Mullen

Kelly Mullen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10273238
    Abstract: The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: April 30, 2019
    Assignee: AbbVie Inc.
    Inventors: Eric C. Breinlinger, Andrew Burchat, Justin Dietrich, Michael Friedman, David Ihle, David Kinsman, Kelly Mullen, Augustine Osuma, Anil Vasudevan, Noel S. Wilson
  • Patent number: 10160748
    Abstract: The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: December 25, 2018
    Assignee: AbbVie Inc.
    Inventors: Maria Argiriadi, Eric Breinlinger, Justin D. Dietrich, Michael Friedman, David Ihle, Michael Morytko, Kelly Mullen, Augustine Osuma, Gloria Y. LoSchiavo, Noel S. Wilson
  • Publication number: 20180215764
    Abstract: The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: December 22, 2017
    Publication date: August 2, 2018
    Inventors: Eric C. Breinlinger, Andrew Burchat, Justin D. Dietrich, Michael Friedman, David Ihle, David Kinsman, Kelly Mullen, Augustine T. Osuma, Anil Vasudevan, Noel S. Wilson
  • Publication number: 20180086737
    Abstract: The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.
    Type: Application
    Filed: August 7, 2017
    Publication date: March 29, 2018
    Inventors: Maria Argiriadi, Eric Breinlinger, Justin D. Dietrich, Michael Friedman, David Ihle, Michael Morytko, Kelly Mullen, Augustine Osuma, Gloria Y. LoSchiavo, Noel S. Wilson
  • Patent number: 9879016
    Abstract: The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: January 30, 2018
    Assignee: AbbVie Inc.
    Inventors: Eric Breinlinger, Andrew Burchat, Justin Dietrich, Michael Friedman, David Ihle, David Kinsman, Kelly Mullen, Augustine Osuma, Anil Vasudevan, Noel Wilson
  • Publication number: 20160304526
    Abstract: The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 20, 2016
    Inventors: Eric Breinlinger, Andrew Burchat, Justin Dietrich, Michael Friedman, David Ihle, David Kinsman, Kelly Mullen, Augustine Osuma, Anil Vasudevan, Noel Wilson
  • Publication number: 20160304496
    Abstract: The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 20, 2016
    Inventors: Maria Argiriadi, Eric Breinlinger, Justin D. Dietrich, Michael Friedman, David Ihle, Michael Morytko, Kelly Mullen, Augustine Osuma, Glora Y. Lo Schiavo, Noel S. Wilson
  • Publication number: 20070282101
    Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.
    Type: Application
    Filed: April 2, 2007
    Publication date: December 6, 2007
    Inventors: Anna Ericsson, Andrew Burchat, Kristine Frank, David Calderwood, Lily Abbott, Maria Argiriadi, David Borhani, Kevin Cusack, Richard Dixon, Thomas Gordon, Kelly Mullen, Robert Talanian, Xiaoyun Wu, Xiaolei Zhang, Lu Wang, Biqin Li, Claude Barberis, Neil Wishart
  • Publication number: 20070155776
    Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Application
    Filed: February 15, 2007
    Publication date: July 5, 2007
    Inventors: Patrick Betschmann, Andrew Burchat, David Calderwood, Michael Curtin, Steven Davidsen, Heather Davis, Robin Frey, Howard Heyman, Gavin Hirst, Peter Hrnciar, Michael Michaelides, Melanie Muckey, Kelly Mullen, Paul Rafferty, Carol Wada